Amyvid Approval History

  • FDA approved: Yes (First approved April 6th, 2012)
  • Brand name: Amyvid
  • Generic name: florbetapir F 18
  • Company: Eli Lilly and Company and Avid Radiopharmaceuticals, Inc.
  • Treatment for: Diagnosis and Investigation

Amyvid (florbetapir F 18) is a radioactive diagnostic agent used for brain imaging of beta-amyloid plaques in patients who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.

FDA Approval History for Amyvid

DateArticle
Apr  9, 2012Approval FDA Approves Amyvid (Florbetapir F 18 Injection) for Use in Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive Decline
Mar 18, 2011Lilly and Avid Receive Complete Response Letter from FDA for Amyvid (florbetapir F 18 injection)

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web1)